A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial

被引:13
|
作者
Gelman, Ram [1 ,2 ]
Hurvitz, Noa [1 ,2 ]
Nesserat, Rima [1 ,2 ]
Kolben, Yotam [1 ,2 ]
Nachman, Dean [2 ,3 ]
Jamil, Khurram [4 ]
Agus, Samuel [4 ]
Asleh, Rabea [2 ,3 ]
Amir, Offer [2 ,3 ]
Berg, Marc [4 ]
Ilan, Yaron [1 ,2 ,5 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Med, Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel
[3] Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Cardiol, Jerusalem, Israel
[4] Stanford Univ, Oberon Sci & Area 9 Innovat, Palo Alto, CA USA
[5] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Med, POB 1200, Jerusalem, Israel
关键词
Congestive heart failure; Diuretic resistance; Artificial intelligence; RATE-VARIABILITY; DRUG-RESISTANCE; IMMUNE-SYSTEM; PLATFORM; CHRONOBIOLOGY; CHRONOTHERAPY; MICROTUBULES; DYNAMICS;
D O I
10.1016/j.biopha.2023.114334
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: Diuretics are a mainstay therapy for congestive heart failure (CHF); however, over one-third of patients develop diuretic resistance. Second-generation artificial intelligence (AI) systems introduce variability into treatment regimens to overcome the compensatory mechanisms underlying the loss of effectiveness of diuretics. This open-labeled, proof-of-concept clinical trial sought to investigate the ability to improve diuretic resistance by implementing algorithm-controlled therapeutic regimens.Methods: Ten CHF patients with diuretic resistance were enrolled in an open-labeled trial where the Altus CareTM app managed diuretics' dosage and administration times. The app provides a personalized therapeutic regimen creating variability in dosages and administration times within pre-defined ranges. Response to therapy was measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) score, 6-minute walk test (SMW), N -terminal pro-brain natriuretic peptide (NT-proBNP) levels, and renal function.Results: The second-generation, AI-based, personalized regimen alleviated diuretic resistance. All evaluable patients demonstrated clinical improvement within ten weeks of intervention. A dose reduction (based on a three-week average before and last three weeks of intervention) was achieved in 7/10 patients (70 %, p = 0.042). The KCCQ score improved in 9/10 (90 %, p = 0.002), the SMW improved in 9/9 (100 %, p = 0.006), NT-proBNP was decreased in 7/10 (70 %, p = 0.02), and serum creatinine was decreased in 6/10 (60 %, p = 0.05). The intervention was associated with reduced number of emergency room visits and the number of CHF-associated hospitalizations.Summary: The results support that the randomization of diuretic regimens guided by a second-generation personalized AI algorithm improves the response to diuretic therapy. Prospective controlled studies are needed to confirm these findings.
引用
收藏
页数:6
相关论文
共 4 条
  • [1] AN ARTIFICIAL INTELLIGENCE BASED THERAPEUTIC REGIMEN IMPROVES DIURETIC RESISTANCE IN HEART FAILURE
    Berg, Marc
    Gelman, Ram
    Hurvitz, Noa
    Neserat, Rima
    Kolben, Yotam
    Nachman, Dean
    Jamil, Khurram
    Agus, Shmuel
    Asleh, Rabea
    Amir, Offer
    Ilan, Yaron
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (08) : 2210 - 2210
  • [2] A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
    Hurvitz, Noa
    Dinur, Tama
    Revel-Vilk, Shoshana
    Agus, Samuel
    Berg, Marc
    Zimran, Ari
    Ilan, Yaron
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (11)
  • [3] Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
    Sigawi, Tal
    Gelman, Ram
    Maimon, Ofra
    Yossef, Amal
    Hemed, Nila
    Agus, Samuel
    Berg, Marc
    Ilan, Yaron
    Popovtzer, Aron
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [4] REDUCING SCREEN FAILURE RATES FOR NASH CLINICAL TRIALS USING BALLOONING AND FIBROSIS ASSESSMENT WITH SECOND HARMONIC GENERATION/ TWO-PHOTON EXCITATION MICROSCOPY AND ARTIFICIAL INTELLIGENCE ANALYSIS: RESULTS FROM THE TANDEM TRIAL
    Akbary, Kutbuddin
    Ren, Ya-Yun
    Tai, Dean
    Alkhouri, Naim
    Brees, Dominique
    Kochuparampil, Jossy
    HEPATOLOGY, 2023, 78 : S866 - S868